News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GTx, Inc. (GTXI) Plummets to a New Low After Drug Fails Late-Stage Trials


8/19/2013 7:47:14 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value of the once-promising cancer-focused pharmaceutical company.

GTx said on Monday that the drug, enobosarm, failed to meet the twin goals of improving body mass and physical function in cancer patients — the latter measured by improvement in their ability to climb stairs.

Help employers find you! Check out all the jobs and post your resume.

Read at Street Insider
Read at Reuters
Read at RTT News
Read at Bloomberg

comments powered by Disqus
GTx, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES